Rostec develops a vaccine in cooperation with Indian partners

Rostec develops a vaccine in cooperation with Indian partners
Rostec develops a vaccine in cooperation with Indian partners

Rostec’s subsidiary Nacimbio has completed the first phase of clinical trials of the rotavirus vaccine. The new drug will be packaged in Russia in 2020 already, while the full production cycle will be launched in 2026.

Rostec’s subsidiary National Immunobiological Company (Nacimbio) localizes production of the rotavirus vaccine in Russia in accordance with the agreement with Indian partners. An exclusive agreement on transfer of vaccine production technologies was signed by Farm Aid Ltd. (established by National Immunobiological Company in cooperation with Ishvan Pharmaceuticals, UAE) and the two largest global biotechnology companies, Serum Institute of India and Zydus Cadila (Healthcare) in 2017.

It is planned that by 2020, the Russian company will package the vaccine.  The full production cycle, including production of antigens, will be launched in 2026. The project is a result of integration in the sphere of pharmaceutical manufacturing carried out by the holding company.

“The Russian Ministry of Healthcare aims to add rotavirus vaccines to the National Immunization Calendar  in 2020. By this time we will be able to fully meet the needs stated in the government order. The supply of the rotavirus vaccine in the interests of the Ministry of Healthcare may total 4.5 million doses per year,” said Executive Director of Rostec Oleg Yevtushenko.

The BIOTECHMED forum is held in Gelendzhik from September 9 through September 11, 2018. It is a combination of an academic conference (in terms of giving experts an opportunity to exchange opinions) and a display area to provide for relevant and objective assessment of industry development prospects and making informed decisions. BIOTECHMED aims to make market participants interested in synergy to ensure transition to medicine of new generation and to form common understanding of problems, tasks and opportunities. The conference will be attended by more than 1,500 representatives of the business and academic community of Russia and other countries.

The National Immunobiological Company (Nacimbio)was established in order to create a holding company (integrated structure) of Rostec in the sphere of development and production of immunobiological products. The holding company is meant to ensure Russia’s independence from imports in the sphere of healthcare and provision of drugs. To achieve this, the holding company comprises Microgen Scientific-cum-Production Association, FORT Ltd, and SintezPubl.Corp.

Farm Aid Ltd. was established on May 26, 2017 as a joint venture of Nacimbio representing Rostec’s pharmaceutical holding company, and Ishvan Pharmaceutical Ltd (UAE). Ishvan has a 51% stake in Farm Aid Ltd., while the share of Nacimbio is 49%. The company’s key objectives include transfer of technologies, localization of innovative combined and immunobiological drugs production in Russia, and ensuring easier availability of effective therapy for Russian patients. Due to the project implementation, new Russian drugs which have not been on the market will be available at a reasonable price and will ensure saving of the federal healthcare budget.

Rostec Corporation is a Russian corporation that was established in 2007 to facilitate the development, production and export of high-tech industrial products designed for civilian and military applications. The Corporation comprises over 700 organizations that are currently part of eleven holding companies operating in the military-industrial complex and four holding companies working in civilian industry, as well as over 80 directly managed organizations. Rostec’s portfolio includes well-known brands such as AVTOVAZ, KAMAZ, Concern Kalashnikov, Russian Helicopters, UralVagonZavod, etc. Rostec companies are located in 60 constituent entities of the Russian Federation and supply products to the markets of more than 100 countries. In 2017 the consolidated revenue of Rostec reached 1 trillion 589 billion rubles, while the consolidated net income and EBITDA amounted to 121 and 305 billion rubles respectively. In 2017 the average salary in the Corporation was 46,800 rubles. According to Rostec’s strategy, the main objective of the Corporation is to ensure that Russia has a technological advantage in highly competitive global markets. Rostec’s key objectives include the introduction of a new techno-economic paradigm and digitalization of Russian economy.

Disclaimer: The views of authors published on South Africa Today are their own and do not necessarily represent the views of South Africa Today. By viewing, visiting, using, or interacting with, you are agreeing to all the provisions of the Terms of Use Policy and the Privacy Policy.